Prochymal®, mesenchymal stem cells for treatment of acute myocardial infarction

Prochymal® is an intravenously administered formulation of mesenchymal stem cells (MSCs). Prochymal® was tested to establish the safety and efficacy in patients following first acute myocardial infarction (MI). It was found that intravenously administered allogeneic MSCs are safe in patients after acute MI. This trial provides pivotal safety and provisional efficacy data for an allogeneic bone marrow-derived stem cell in post-infarction patients.